All In Biotech

Drug Trial Radar · NCT06442462

Study of SPG302 in Adults With Schizophrenia

A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Mar 2026

Study completion Mar 2026

Sponsor

Lead sponsor
SpinogenixIndustry
Sponsor type
Industry
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • SPG302Drug

    small synthetic molecule

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive and Negative Symptoms Scale (PANSS Score) as determined by clinicianTime frame: 6 weeks
  2. Electroencephalogram analysis to assess brain electrical activityTime frame: 6 weeks
  3. Change in smooth pursuit eye tracking from baselineTime frame: 6 weeks

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • CenExel CNS

    Garden Grove, California

  • Box Hill Hospital - Eastern Health

    Box Hill, Victoria, Australia

  • Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.